MedTrace Logo

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A

NCT02610127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2021-08-05

No results posted yet for this study

Summary

The overall objective is to enroll patients with acquired hemophilia A (AHA) who are prescribed and treated with Obizur, to assess safety, and to describe factors related to safety, utilization and effectiveness in a real-world setting.

Conditions

  • Acquired Hemophilia A

Interventions

BIOLOGICAL

OBIZUR

Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.

Sponsors & Collaborators

  • Baxalta Innovations GmbH, now part of Shire

    collaborator INDUSTRY

  • Baxalta now part of Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Shire

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-30
Primary Completion
2019-06-07
Completion
2019-06-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02610127 on ClinicalTrials.gov